GlassScriptPhysician profile
Robert A Engel
NPI 1760460521
$5,071.29
in general payments reported to CMS, 2019-2025
18 companies · $220 in 2025
The $220 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,436 · 2020: $342 · 2021: $567 · 2022: $988 · 2023: $683 · 2024: $835 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,738.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,121.40 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $999.19 | 2019-2024 | Xarelto |
| Medtronic, INC. | $633.12 | 2019-2023 | Micra |
| Boston Scientific Corporation | $398.68 | 2019-2025 | Watchman Flx, Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $366.78 | 2021-2024 | Farxiga, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $268.28 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $252.42 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $223.16 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $168.38 | 2019-2020 | |
| Pfizer Pharmaceuticals LLC | $132.05 | 2019 | |
| Abbott Laboratories | $121.35 | 2021 | |
| Merck Sharp & Dohme LLC | $112.83 | 2022-2023 | Verquvo |
| Edwards Lifesciences Corporation | $74.57 | 2024 | |
| Pfizer INC. | $72.68 | 2025 | |
| Pbg Puerto Rico LLC | $60.82 | 2020-2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $22.30 | 2019 | |
| Allergan, INC. | $21.95 | 2019 | |
| Abbvie INC. | $21.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Engel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.